For example, modulation of irisin concentrations were described in obese subjects, in patients with type 2 diabetes (T2DM) [53], chronic renal disease (CKD) [54], and hypothyroidism [55]. This evidence concerns the gene FNDC5 and type 2 diabetes mellitus.